Technical Analysis for ATRS - Antares Pharma, Inc.

Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies, and topical gel-based medicines worldwide. The company's products include Tjet/Zomajet, the needle-free auto injectors to deliver human growth hormone treatment to children without the use of a needle; twin-jector EZ II needle free injectors; Medi-Jet auto injectors; Elestrin, an estrogen replacement gel for the treatment of hot flashes; and Gelnique 3%, an oxybutynin gel product for the treatment of overactive bladder. The company is also developing OTREXUP, a product for the delivery of methotrexate using Medi-Jet technology for the treatment of rheumatoid arthritis, poly-articular-course juvenile rheumatoid arthritis, and psoriasis; and VIBEX QS T, an auto injector for the treatment of testosterone deficiency or replacement therapy. In addition, it is developing Vibex auto injectors; disposable pen injectors; and Nestragel, a contraceptive gel. Antares Pharma, Inc. has collaborative and license agreements with Ferring Pharmaceuticals BV; Teva Pharmaceutical Industries, Ltd.; JCR Pharmaceuticals Co., Ltd.; Actavis, Inc.; Daewoong Pharmaceuticals; BioSante Pharmaceuticals, Inc.; Meda Pharmaceuticals; Population Council; and Pfizer Inc. The company was founded in 1979 and is headquartered in Ewing, New Jersey.
Biotechnology Health Pharmaceutical Pharmacology Psoriasis Rheumatoid Arthritis Medical Equipment Overactive Bladder Testosterone Deficiency Teva Pharmaceutical Industries